Literature DB >> 10800068

Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation.

D Azoulay1, D Castaing, A Lemoine, G M Hargreaves, H Bismuth.   

Abstract

Severe veno-occlusive disease (VOD) of the liver is a leading cause of mortality after bone marrow transplantation (BMT). Vascular and parenchymal injuries account for acute portal hypertension and liver failure is frequently present. We describe the results of transjugular intrahepatic portosystemic shunt (TIPS) for the management of VOD after BMT. TIPS was performed in 10 patients with histologically proven severe VOD. Portal hypertension was controlled by TIPS in all patients (mean hepatic venous pressure gradient before, 20 +/- 11 vs 6 +/- 5 mm Hg after TIPS, P < 0.01) without technical complications. Five patients with rapidly worsening VOD died within 10 days of TIPS without any improvement. The five remaining patients with less advanced disease showed improvement in various clinical and biological parameters. Four patients subsequently died. The lone survivor continues to do well with resolution of VOD 6 months after TIPS. TIPS can be performed safely and controls portal hypertension in VOD after BMT. Arguments from the present series and from eight previously reported cases favour earlier application of TIPS to obtain improved overall survival. Bone Marrow Transplantation (2000) 25, 987-992.

Entities:  

Mesh:

Year:  2000        PMID: 10800068     DOI: 10.1038/sj.bmt.1702386

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  16 in total

1.  Veno-occlusive Disease.

Authors:  Ira R. Willner
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

Review 2.  Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage.

Authors:  Romaric Loffroy; Louis Estivalet; Violaine Cherblanc; Sylvain Favelier; Pierre Pottecher; Samia Hamza; Anne Minello; Patrick Hillon; Pierre Thouant; Pierre-Henri Lefevre; Denis Krausé; Jean-Pierre Cercueil
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

Review 3.  Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up.

Authors:  Alexander Copelan; Baljendra Kapoor; Mark Sands
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

Review 4.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors:  Cathy Q Fan; James M Crawford
Journal:  J Clin Exp Hepatol       Date:  2014-10-30

Review 5.  Transjugular intrahepatic portosystemic shunt.

Authors:  Kavish R Patidar; Malcolm Sydnor; Arun J Sanyal
Journal:  Clin Liver Dis       Date:  2014-08-27       Impact factor: 6.126

6.  Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis.

Authors:  Harjit K Bhogal; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2011-06-21       Impact factor: 11.382

Review 7.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 8.  Current use of transjugular intrahepatic portosystemic shunts.

Authors:  Timothy M McCashland
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 9.  Hepatic venous outflow obstruction: three similar syndromes.

Authors:  Ulas-Darda Bayraktar; Soley Seren; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

Review 10.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; R F Duarte; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; T Pagluica; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; E Carreras
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.